Siste 50 endringer

Ped lymfom 067 B-NHL IKKE STUDIE CC Cytara/deks/eto/vindesin/it trippel

Ped lymfom 049 LBL 2018 STUDIE HR blokk 2, forsterket protokoll M

Ped lymfom 033 B-NHL STUDIE CC Cytara/deks/eto/vindesin/it trippel

Ped lymfom 016 ALCL relapse CC, Cyt/deks/eto/vindesin/it trippel

Mage-tarm 195 Cadd Solis Etoposid/karboplatin AUC5

Mage-tarm 132ab MiFu Fluorouracil/mitomycin infusor/CADD Solis

Lunge 124-125 V940-02 Pembrolizumab + V940/placebo

Ped ALL 143ab, 144abc Interfant-21 Blinatumomab

Ped AML 022, 023, 024, 025 AML residiv FLAD-FLA

PIPERACILLIN/TAZOBACTAM

ENDRINGER I KURER I CMS

Mage-tarm 032 Karboplatin AUC2/paklitaksel

Urologi 019ab Cisplatin/gemcitabin -21

Urologi 020abc Cisplatin/gemcitabin -21, nyresparende

Lunge 001 Cisplatin/vinorelbin

Felles 098 Cisplatin/etoposid iv/po

Felles 098 Cisplatin/etoposid iv/po

Felles 098 Cisplatin/etoposid iv/po

Felles 098 Cisplatin/etoposid iv/po

ØNH 041-042 JADE/221530 Dostarlimab/placebo

Lunge 111ab Atezolizumab sc/etoposid iv±po/karboplatin AUC5

Mage-tarm 022abc Gemcitabin

Felles 145 Atezolizumab sc/bevacizumab

Felles 144 Atezolizumab sc 1875 mg

Bryst 093 Atezolizumab sc/paklitakselalbumin

Blod 466ab Obinutuzumab monoterapi

Blod 472ab MagnetisMM-32 arm B PVd Bortezomib

Blod 471ab MagnetisMM-32 arm B EPd Elotuzumab

Bryst 086 Karboplatin -7, AUC2

Bryst 084 Gemcitabin/karboplatin AUC2/pembrolizumab

Bryst 081 Karboplatin AUC2/paklitaksel 80 mg/m2 dag 1,8,15

KARFILZOMIB

Ped lymfom 025 B-NHL STUDIE B4-R2 st III Doks/mtx/sykl/vink/it trippel

Ped lymfom 030abc B-NHL STUDIE AA24-Z1-Z2 Cytara/etoposid/mtx 5g/ifos/it

Ped lymfom 023-024 B-NHL STUDIE b4-R1-R2

Ped lymfom 031 B-NHL STUDIE AA8Z1 Cyt/eto/ifos/mtx 8g/it, CNS+

Ped lymfom 021-022 B-NHL studie A4-R1-R2

Ped lymfom 032abc B-NHL STUDIE BB24-Z1-Z2 Dokso/mtx/syklo/vinkr/it trippel

Ped lever 030ab Dokso/karbo gruppe C, IKKE STUDIE

Ped lever 023-024 Cisplatin m/u doksorubicin IKKE STUDIE

Ped lever 031 PLADO Cisplatin 80/dokso 30, HCC, IKKE STUDIE

Ped lymfom 034-035 B-NHL STUDIE Enkelt/dobbelt-dose rituksimab

Ped lymfom 036 ALCL relapse ICI, Idarubicin/ifos/karbo/it trippel

Ped lymfom 015 BM (ALCL-99/ALCL-13) Deksa/doks/3g mtx/syklo

Ped lymfom 018-018abc OEPA Dokso/etoposid/vcr/pred

Ped lymfom 037 ALCL relapse CVA, CCNU/vinblastin/cytarabin

Ped lymfom 038 mCOMP Syklofosfamid/vinkristin/pred v. PTLD

Ped lymfom 020-020ab DECOPDAC-21

Ped lymfom 039 mCOMP Metotreksat v. PTLD

Ped lymfom 040 LBL 2018 IKKE STUDIE Syklofosfamid ved stor mediastinal tumor